OptiBiotix Health jumps on novel sugar substitute update
The sugar substitutes market is projected to reach US$24.3bn by 2028, driven by demand for healthier, low-calorie options. However, widely used sugar substitutes have potentially negative health effects, including increased blood sugar levels, DNA damage, and possible carcinogenic effects. OptiBiotix addresses a clear market need for better alternatives with its SweetBiotix product portfolio, which includes patented, zero, or low-calorie sweet dietary fibers. SweetBiotix fibers have a prebiotic effect, promoting the production of short-chain fatty acids in the gut, offering additional health benefits.
OptiBiotix has partnerships with industry leaders like Kellogg's, Nestle, Coca Cola. The company is scaling up its manufacturing process to meet the demands of these partnerships, securing manufacturing agreements with US and Firmenich. These partnerships endorse the science underpinning SweetBiotix, and its commercial potential.
The company is in the final stages of manufacturing scale-up and testing for its products. It expects to receive test results over the summer, which will allow it to move forward with partner application development and launch plans.
View from Vox
OptiBiotix has demonstrated, through progress made in commercial-scale production and the positive feedback from partners, that the science and potential of its SweetBiotix product range are likely to position it as a key player in the sugar substitutes market. Investors have reacted positively to the news, pushing OptiBiotix shares up 51% at time of writing.
More broadly, OptiBiotix develops microbial strains, compounds, and formulations that modify the human microbiome. These innovations serve as active ingredients in a range of products and supplements, with a particular focus on obesity, cardiovascular health, and diabetes.
The above three diseases are recognised as global health priorities, with cardiovascular disease being the leading cause of death globally, taking an estimated 17.9 million lives each year, along with 537 million adults suffering from diabetes.
OptiBiotix has hit a number of key milestones since admission to the AQSE Growth Market in March 2022, launching LeanBiome within well-esteemed e-commerce retail company The Hut Group’s lean product range; and making its mark globally with the launch of its GoFigure line in India and China.
OptiBiotix continues to see progress across its business, bringing in new customers - in the US with its investment in new e-commerce channels such as Walmart - and in APAC markets. Its heavy investment in e-commerce has led to rapid sales growth, and OptiBiotix should see this momentum continue through 2023 and beyond.
Follow OptiBiotix for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.